18 studies found for:    "Splenomegaly"
Show Display Options
RSS Create an RSS feed from your search for:
"Splenomegaly"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Conditions: Hyper-reactive Malarial Splenomegaly;   Malaria;   Anaemia
Interventions: Drug: prednisone induction - chloroquine;   Drug: Chloroquine
2 Completed Ultrasound Estimation of Spleen Size
Condition: Splenomegaly
Interventions: Device: Vscan Ultrasound (GE Healthcare, USA);   Device: Conventional Ultrasound
3 Completed Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
Conditions: Splenomegaly;   Pleural Effusion
Intervention: Device: resident with GE vscan
4 Completed Spleen Size in Peripheral Blood Stem Cell Donors
Condition: Splenomegaly
Intervention:
5 Completed Estimation of Spleen by Residents With VScan
Condition: Splenomegaly
Intervention: Device: VScan Ultrasound (GE Healthcare, USA)
6 Unknown  Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Conditions: Liver Cirrhosis;   Carcinoma, Hepatocellular;   Splenomegaly;   Laparotomy
Intervention:
7 Completed Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Condition: Myelofibrosis
Intervention: Drug: SAR302503
8 Completed Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503;   Drug: Placebo
9 Completed Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
10 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
11 Completed Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder
Intervention: Drug: Pyrimethamine
12 Completed Prospective Randomized Comparison of Clinical Results of Hand Assisted Laparoscopic Splenectomies and Open Splenectomies
Condition: Postoperative Pain
Intervention:
13 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
14 Completed
Has Results
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: ALPS;   Hypersplenism;   Lymphadenopathy
Interventions: Drug: Valproic Acid;   Procedure: CT Scan;   Procedure: Blood Sample
15 Active, not recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
16 Completed Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphoproliferative Disorder
Intervention: Drug: Fansidar (pyrimethamine and sulfadoxine)
17 Unknown  Hemolysis in Patients With Hereditary Spherocytosis (HS)
Conditions: Hereditary;   Hemolysis
Intervention: Other: fermented papaya preparation (FPP)
18 Recruiting Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)

Indicates status has not been verified in more than two years